(00:32)

Can you tell us a little bit about yourself, your background and your role here at Mayo Clinic?

(01:43)

Can you tell us a little bit about the test and also explain why it was unavailable for a period of time?

(05:46):

I know there must have been a lot of effort and a lot of time put in ensuring that even if it means taking the down and maybe even for financial loss for the Mayo clinic that we get it right.

(06:47):

From what I understand, as I understand it, it's more of an adjunct or a confirmative test that's used. Can you please expand a little bit on that?

(10:18):

Do they always have this done after calprotectin testing, or are they ordered at the same time, in some cases, is there ever a time when you would order both together or is it always one first and then the other?

(11:55):

You just mentioned some of the details behind the results, but some of the studies around the markers used in this test have shown some interesting data around the results being more highly predictive in determining Crohn's disease or ulcerative colitis in pediatric patients. Is that something you're familiar with?

(14:03):

And how does the Mayo Clinic test compare in efficiency or cost?

(17:34):

So we've Discussed quite a bit of information. How does all of this play into patient care?

(18:24):

Is anything else you'd like to add to those who may be considering ordering the IBD P two test through Mayo clinic laboratories, or maybe did in the past, but have switched labs and are still on the fence about coming back to MC for this test?

(0:58)
 Could you tell us a bit about yourself and your background? 
 
 (01:47)
 Could you provide us some background on cobalt and chromium testing, and when these tests are used in patient care?

(03:16)
 You recently completed a study comparing the sensitivity and specificity of cobalt and chromium testing to detect adverse local tissue reactions using synovial fluid versus whole blood samples. Could you tell us more about the study and the results?

(06:12)
 What is your recommendation to physicians treating symptomatic patients with metal-on-metal implants for measuring metal ion levels?

(06:44)
 Could you provide some details on the cobalt and chromium synovial fluid tests available at Mayo Clinic Laboratories? 

(00:32):

Before we get started, can you tell us a little bit about yourself, your background, and your role here at Mayo Clinic?

(01:17):

Will you start by telling us a little bit about what thiopurines are, and give us a brief overview of the test and how the results are used with patients affected by inflammatory bowel syndrome?

(03:21):

If like you said, the patients don't metabolize these drugs, well, you might actually make the situation worse by taking the medications?

(04:03):

According to the Crohn's and ulcerative colitis organizations around six to 10 people with these conditions end up taking these medications at some point in their life, including children, is that correct?
 

(04:38):

So who exactly is this test recommended for it? And when would you say is the best time for the patient to have the test performed? Does the patient wait for the symptoms to arise or is it recommended that the labs are run before the medications are prescribed?

(05:55):

When this test was developed, it was developed for use with all patients in mind, but the studies around the test have shown some really interesting data in regard to certain groups of patients for whom it may be more important. Would you care to expand on that?

(08:35):

If the Patient had not taken this test. How else would the patient be aware of these types of issues? Are there other test options that they could use? And if so, how are those other test options different from what we do here at Mayo Clinic Labs?

(11:05):

Is there anything else you'd like to add to kind of remind someone why they should consider this test?

(00:32) Before we get started, Dr. Willrich, can you give us a quick introduction of yourself and your role here at Mayo Clinic?

(01:13) Can you give us a little bit of background about what kappa free light chain testing is and the importance of the multiple sclerosis test?

(05:01) Can you give us a brief discussion about what this publication means and what it means to patients and physicians as a whole?

(06:12) So when it comes to these methods, what should you tell physicians? You know, why we should use kappa free light chains other than those other methods?

(08:39) When it comes to this new approach, can you tell me about how does this really impact the patients? 

(10:18) Thanks so much for that information, Dr. Willrich , can you tell me, what does this mean for the patients?

(12:08) With you being one of the authors for this publication, can you tell me what this publication means to you and what it should mean to everyone else?

(:52)
Would you mind starting off with telling us a little bit about yourself and your background?

(1:29)
Can you help us understand how knowing urinary ammonium levels help you manage your patients on a day-to-day basis?

(2:58)
Can you help the audience understand the evolution of laboratory tests used to determine urinary ammonium levels and why nephrologists are now recommending using tests that directly measure urinary ammonium instead of the widely accepted urinary ammonium gap estimate?

(6:17)
Can you share a little more information about the tests that we have available and how, and when they should be used in clinical practice?

(7:57)
Finally, what advice do you have for nephrologists that be converting from urine anine gap to direct ammonium testing?